ReviewDrugs2017
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Review in Drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed.
- Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.Clinical and translational science · 2021Trial
- The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.Bulletin of experimental biology and medicine · 2021Trial
- Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods.Chirality · 2026Review
- Plakoglobin phosphorylation at serine 665 is capable of stabilizing cadherin-mediated adhesion in keratinocytes.JCI insight · 2026Article
- Efficacy and Safety of Small Molecule Inhibitor Therapies for Vitiligo: A Systematic Review.Health science reports · 2026Review
- Characterization of the Interaction between Human αACS omega · 2025Article
- Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Can Week 4 PASI Response Serve as an Early Predictor of Apremilast Efficacy in Psoriasis? A Single-Centre Preliminary Study.Acta dermato-venereologica · 2025Article
- Epac1 contributes to apremilast-mediated rescue of pemphigus autoantibody-induced loss of keratinocyte adhesion.JCI insight · 2025Article
- Safety assessment of apremilast: real-world adverse event analysis from the FAERS database.Archives of dermatological research · 2025Article
- Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.Pharmaceutics · 2025Review
- Skin immune microenvironment in psoriasis: from bench to bedside.Frontiers in immunology · 2025Review
- Advances in the Drug Delivery Systems for Psoriasis Topical Therapy.International journal of nanomedicine · 2025Review
- Apremilast in osteoarthritis: exploring its therapeutic mechanisms.Drugs in context · 2025Review
- Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis.Psoriasis (Auckland, N.Z.) · 2025Article
- Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments.Journal of inflammation research · 2025Review
- Phosphodiesterase inhibition and Gucy2C activation enhance tyrosine hydroxylase Ser40 phosphorylation and improve 6-hydroxydopamine-induced motor deficits.Cell & bioscience · 2024Article
- Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.The Journal of dermatology · 2024Article
- The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies.Acta pharmaceutica Sinica. B · 2024Review
- Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apremilast (Otezla
Indexed as
Identifiers
28213862What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.